Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Astrocytoma × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 8 Precancerous Conditions 3 Adenomatous Polyposis Coli 3 Sarcoma, Ewing 2 Prostatic Neoplasms 2 Osteosarcoma 2 Glioma 2 Colorectal Neoplasms 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Skin Neoplasms 1 Rhabdoid Tumor 1 Osteosarcoma Recurrent 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Melanoma 1 Medulloblastoma 1 Lung Neoplasms 1 Keratosis, Actinic 1 Esophageal Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Colonic Polyps 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Adenomatous Polyps 1

Interventions

Temozolomide 103 Radiotherapy 56 Carboplatin 28 Bevacizumab 28 Carmustine 26 Magnetic Resonance Spectroscopy 23 Filgrastim 20 Surgical Procedures, Operative 18 Irinotecan 18 Radiation 15 Lomustine 15 Vincristine 14 Etoposide 13 Specimen Handling 11 Radiotherapy, Intensity-Modulated 11 Procarbazine 11 Peripheral Blood Stem Cell Transplantation 11 O(6)-benzylguanine 11 Erlotinib Hydrochloride 11 Cyclophosphamide 11 sargramostim 10 Chemotherapy, Adjuvant 10 Cisplatin 9 antineoplaston AS 2-1 8 antineoplaston A10 8 Thiotepa 8 Granulocyte Colony-Stimulating Factor 8 Flucytosine 8 Everolimus 7 vocimagene amiretrorepvec 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡